ZNF365 and obesity disorder: In our recently study, DBZ, as a promising therapeutic agent for atherogenesis and obesity in the mouse models, inhibits inflammation, macrophage migration, and foam cell formation, possibly through the partial activation of both PPARγ and LXRs.